Pancreatic Clinical Research
CPMC Cancer Services
Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page
Further protocol information can be found on the links below at ClinicalTrials.gov
Active Trials
Title: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer
Description: Immunotherapy Study for Surgically Resected Pancreatic Cancer
Principal Investigator: Ari Baron, MD
Eligibility: Patients with pancreatic cancer that has been surgically removed
Status: Active and open to enrollment
Contact: Laurel Fiske, 415-600-1654,
Email: FiskeL@cpmcri.org about Study NLG0405
Title: Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Description: Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)
Principal Investigator: Ari Baron, MD
Eligibility: Patients with locally advanced pancreatic cancer
Status: Active and open to enrollment
Contact: Laurel Fiske, 415-600-1654,
Email: FiskeL@cpmcri.org about Study Otsuka 287-11-201
Title: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Description: Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Principal Investigators: CPMC Oncologists
Eligibility: Patients with pancreatic cancer that has been surgically removed
Status: Active and open to enrollment
Contact: Laurel Fiske, 415-600-1654,
Email: FiskeL@cpmcri.org about Study RTOG 0848
Title: Randomized Phase II Study of Everolimus and Octreotide Versus Everolimus and Octreotide Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Description: Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Principal Investigators: CPMC Oncologists
Eligibility: Neuroendocrine tumor that has spread to other parts of the body
Status: Active and open to enrollment
Contact: Laurel Fiske, 415-600-1654,
Email: FiskeL@cpmcri.org about Study CALGB 80701
Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer
Description: Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Principal Investigator: Ari Baron, MD
Eligibility: Subjects with advanced pancreatic cancer who have never been treated
Status: Coming soon
Contact: Laurel Fiske, 415-600-1654,
Email: FiskeL@cpmcri.org about Study Halo-109-201
- updated January 2012
Back to top